Grufity logoGrufity logo

JNJ

178.88USD+0.14(+0.08%)Delayed

Johnson & Johnson

Market Summary

USD178.88+0.14Delayed
0.08%

JNJ Alerts

JNJ Stock Price

RSI Chart

Valuation

Market Cap

459.8B

Price/Earnings

24

Price/Sales

4.79

Price/Cashflow

21.31

MarketCap/EBT

20.56

Price/Sales

Profitability

EBT Margin

23.28%

Return on Equity

25.68%

Return on Assets

10.94%

Fundamentals

Revenue

Revenue (TTM)

96.0B

Revenue Y/Y

1.94%

Revenue Q/Q

-0.95%

Earnings

Earnings (TTM)

19.2B

Earnings Y/Y

21.57%

Earnings Q/Q

-7.4%

Price Action

52 Week Range

152.71183.08
(Low)(High)

Last 7 days

0.9%

Last 30 days

5.6%

Last 90 days

10.6%

Trailing 12 Months

16.9%

Financial Health

Current Ratio

1.43

Debt/Equity

0.42

Debt/Cashflow

0.73

Investor Care

Dividend Yield

2.5%

Dividend/Share (TTM)

4.38

Buy Backs (1Y)

0.69%

Diluted EPS (TTM)

7.18

Peers (Alternatives to Johnson & Johnson)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
5.64% 16.86%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.87% 53.25%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
9.09% -0.90%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.70% 54.15%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.75% 50.97%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.59% -9.60%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
9.23% 20.30%
32.36
2.95
16.78% -53.92%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
16.50% -21.36%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
16.81% -54.64%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
9.62% 31.13%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
0.99% -19.37%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-11.83% -51.92%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Johnson & Johnson

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue0.5%96,04195,58894,88093,77591,446
Gross Profit-0.2%64,76264,86664,49063,92061,732
  S&GA Expenses0.4%25,40725,31825,16524,65923,962
Earnings Before Taxes9.7%22,36020,38721,20922,77619,587
Net Income4.3%19,15718,36619,83020,87817,880
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.5%175,124177,724178,355182,018179,228
  Current Assets2.2%65,23663,84760,42460,97959,889
    Cash Equivalents3.4%11,35510,98310,46314,48717,604
  Inventory2.1%11,67511,43710,99010,38710,387
  Net PPE-1.1%18,15218,35418,70118,96218,478
  Goodwill-2.3%33,38334,16634,93535,24635,569
Liabilities-0.8%100,525101,367103,646107,995108,956
  Current Liabilities1.6%45,54344,82143,39045,22644,561
.    Short Term Borrowings2.8%4,4244,3054,2973,7663,798
  Long Term Debt-32,116----
    LT Debt, Current-2,131----
    LT Debt, Non Current-2.4%27,60328,29228,85129,98530,130
Shareholder's Equity-2.3%74,59976,35774,70974,02370,272
  Retained Earnings1.3%127,917126,216124,380123,060121,092
Accumulated Depreciation-0.9%28,52928,79029,00128,71728,869
Shares Outstanding0.0%2,6302,6292,633--
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-8.5%21,57623,58223,31523,41026,021
  Share Based Compensation2.0%1,1401,1181,1061,1351,080
Cashflow From Investing7.1%-13,334.00-14,352.00-12,132.00-8,683.00-11,226.00
Cashflow From Financing-14.0%-14,007.00-12,289.00-13,307.00-14,047.00-16,255.00
  Buy Backs45.1%5,7113,9373,5953,4562,781

Risks

What is the probability of a big loss on JNJ?

17.7%


Probability that Johnson & Johnson stock will be more than 20% underwater in next one year

0%


Probability that Johnson & Johnson stock will be more than 30% underwater in next one year.

0%


Probability that Johnson & Johnson stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JNJ drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Johnson & Johnson was unfortunately bought at previous high price.

Returns

Cumulative Returns on JNJ

12.9%


10-Year Cumulative Returns

11.1%


7-Year Cumulative Returns

7.8%


5-Year Cumulative Returns

12.1%


3-Year Cumulative Returns

What are the long-term rolling returns for JNJ?

FIve years rolling returns for Johnson & Johnson.

Which funds bought or sold JNJ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
SALEM CAPITAL MANAGEMENT INC
UNCHANGED
-
-295,000
3,402,000
2.69%
2022-11-29
London & Capital Asset Management Ltd
ADDED
2.19
-2,593,000
40,962,000
3.82%
2022-11-29
Bridgefront Capital, LLC
NEW
-
342,000
342,000
0.35%
2022-11-29
AWM CAPITAL, LLC
ADDED
27.38
101,000
473,000
0.16%
2022-11-23
FSB PREMIER WEALTH MANAGEMENT, INC.
REDUCED
-1.05
-88,000
894,000
0.52%
2022-11-23
Toroso Investments, LLC
ADDED
30.23
2,485,000
15,006,000
0.62%
2022-11-23
Gould Capital, LLC
UNCHANGED
-
-1,000
20,000
0.02%
2022-11-23
Invst, LLC
ADDED
2.3
-63,000
1,581,000
0.27%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-2.51
-95,651
852,000
0.53%
2022-11-22
Gibson Wealth Advisors LLC
UNCHANGED
-
-4,000
47,000
0.05%

1–10 of 48

Latest Funds Activity

Are funds buying JNJ calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own JNJ

Johnson & Johnson News

Seeking Alpha

Johnson & Johnson: Time To Buy Before The Split (NYSE:JNJ).7 hours ago

JNJ Fair Value

Recent SEC filings of Johnson & Johnson

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 21, 2022
4
Insider Trading
Nov 15, 2022
SC TO-T
SC TO-T
Nov 14, 2022
3
Insider Trading
Nov 14, 2022
SC 13G/A
Major Ownership Report
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
13F-HR
Fund Holdings Report
Nov 09, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 07, 2022
SC TO-C
SC TO-C

Latest Insider Trading transactions for JNJ

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-30
McEvoy Ashley
SOLD
-12,865,800
175.467
-73,323
EVP, WW Chair, MedTech
2022-11-30
McEvoy Ashley
ACQUIRED
5,318,850
72.54
73,323
EVP, WW Chair, MedTech
2022-11-22
Taubert Jennifer L
ACQUIRED
5,579,990
72.54
76,923
EVP, WW Chair, Pharmaceuticals
2022-11-22
Taubert Jennifer L
SOLD
-13,598,400
176.779
-76,923
EVP, WW Chair, Pharmaceuticals
2022-11-18
Decker Robert J
ACQUIRED
1,530,970
90.44
16,928
Controller, CAO
2022-11-18
Decker Robert J
SOLD
-2,962,400
175
-16,928
Controller, CAO
2022-11-09
Wengel Kathryn E
SOLD
-2,845,770
173.417
-16,410
EVP, Chief GSC Officer
2022-11-09
Wengel Kathryn E
ACQUIRED
1,190,380
72.54
16,410
EVP, Chief GSC Officer
2022-11-07
Mongon Thibaut
ACQUIRED
1,874,630
109.994
17,043
Exec VP, WW Chair, Consumer
2022-11-04
Mongon Thibaut
SOLD
-6,033,300
171.177
-35,246
Exec VP, WW Chair, Consumer

1–10 of 50

Joaquin Duato
65535
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

JNJ Income Statement

2022-10-02
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Oct. 02, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Income Statement [Abstract]    
Sales to customers$ 23,791$ 23,338$ 71,237$ 68,971
Sales to customers percent to sales100.00%100.00%100.00%100.00%
Cost of products sold$ 7,807$ 7,250$ 23,324$ 21,900
Cost of products sold percent to sales32.80%31.10%32.70%31.80%
Gross profit$ 15,984$ 16,088$ 47,913$ 47,071
Gross Profit Percent To Sales67.20%68.90%67.30%68.20%
Selling, marketing and administrative expenses$ 6,089$ 6,000$ 18,253$ 17,505
Selling marketing and administrative expenses percent to sales25.60%25.70%25.70%25.40%
Research and development expense$ 3,597$ 3,422$ 10,762$ 9,994
Research and development expense percent to sales15.10%14.70%15.10%14.50%
In-process research and development$ 0$ 900$ 610$ 900
In-process research and development percent to sales0.00%3.90%0.90%1.30%
Interest income$ (150)$ (13)$ (236)$ (40)
Interest income percent to sales(0.60%)(0.10%)(0.30%)(0.10%)
Interest expense, net of portion capitalized$ 51$ 20$ 99$ 123
Interest expense, net of portion capitalized percent to sales0.20%0.10%0.10%0.20%
Other (income) expense, net$ 493$ 1,850$ 664$ 480
Other (income) expense, net percent to sales2.10%7.90%0.90%0.70%
Restructuring (Note 12)$ 82$ 60$ 237$ 169
Restructuring charge percent to sales0.30%0.20%0.30%0.20%
Earnings before provision for taxes on income$ 5,822$ 3,849$ 17,524$ 17,940
Earnings before provision for taxes on income percent to sales24.50%16.50%24.60%26.00%
Provision for taxes on income (Note 5)$ 1,364$ 182$ 3,103$ 1,798
Provision for taxes on income percent to sales5.80%0.80%4.40%2.60%
Net earnings$ 4,458$ 3,667$ 14,421$ 16,142
Net earnings percent to sales18.70%15.70%20.20%23.40%
NET EARNINGS PER SHARE    
Basic (per share)$ 1.70$ 1.39$ 5.49$ 6.13
Diluted (per share)$ 1.68$ 1.37$ 5.41$ 6.04
AVG. SHARES OUTSTANDING    
Basic (shares)2,627.92,632.62,628.92,632.2
Diluted (shares)2,661.32,674.92,667.52,674.6

JNJ Balance Sheet

2022-10-02
Consolidated Balance Sheets - USD ($)
$ in Millions
Oct. 02, 2022
Jan. 02, 2022
Current assets:  
Cash and cash equivalents$ 11,355$ 14,487
Marketable securities22,72417,121
Accounts receivable, trade, less allowances $201 (2021, $230)15,89015,283
Inventories (Note 2)11,67510,387
Prepaid expenses and other3,5923,701
Total current assets65,23660,979
Property, plant and equipment at cost46,68147,679
Less: accumulated depreciation(28,529)(28,717)
Property, plant and equipment, net18,15218,962
Intangible assets, net (Note 3)40,33646,392
Goodwill (Note 3)33,38335,246
Deferred taxes on income (Note 5)9,39210,223
Other assets8,62510,216
Total assets175,124182,018
Current liabilities:  
Loans and notes payable4,4243,766
Accounts payable10,15311,055
Accrued liabilities11,95313,612
Accrued rebates, returns and promotions14,02112,095
Accrued compensation and employee related obligations3,0063,586
Accrued taxes on income (Note 5)1,9861,112
Total current liabilities45,54345,226
Long-term debt (Note 4)27,60329,985
Deferred taxes on income (Note 5)4,9467,487
Employee related obligations (Note 6)8,3538,898
Long-term taxes payable (Note 5)4,1625,713
Other liabilities9,91810,686
Total liabilities100,525107,995
Commitments and Contingencies (Note 11)
Shareholders’ equity:  
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)3,1203,120
Accumulated other comprehensive income (loss) (Note 7)(15,292)(13,058)
Retained earnings127,917123,060
Less: common stock held in treasury, at cost (502,961,000 and 490,878,000 shares)41,14639,099
Total shareholders’ equity74,59974,023
Total liabilities and shareholders' equity$ 175,124$ 182,018